Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
about
Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
P2860
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Second line treatments in adva ...... critical review of literature.
@en
Second line treatments in adva ...... critical review of literature.
@nl
type
label
Second line treatments in adva ...... critical review of literature.
@en
Second line treatments in adva ...... critical review of literature.
@nl
prefLabel
Second line treatments in adva ...... critical review of literature.
@en
Second line treatments in adva ...... critical review of literature.
@nl
P2093
P1476
Second line treatments in adva ...... critical review of literature.
@en
P2093
Carlotta Santelmo
Davide Tassinari
Emiliano Tamburini
Federica Carloni
Luigi Lazzari Agli
Paola Tombesi
Sergio Sartori
P356
10.2174/157488709787047549
P577
2009-01-01T00:00:00Z